^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Oncomine Solid Tumor DNA Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Type:
CE Marked
1year
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study). (ASCO 2023)
These preliminary data suggest a possible prognostic role of TP53 variants in RAS/BRAF wild type mCRC patients receiving first line FOLFIRI/cetuximab followed by Cet alone. Comprehensive genomic profiling is ongoing to identify genomic signatures associated with sensitivity to Cet.
P3 data • Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
TP53 mutation • BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600 • TP53 wild-type • BRAF wild-type
|
Oncomine Solid Tumor DNA Kit
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium
over1year
Preliminary results of mutational analysis in tumor tissue and liquid biopsy in LAHNSCC (ECHNO-ICHNO 2023)
"Conclusion Our preliminary results show good correlation of gene mutation and HPV detection between tumor tissue and baseline LB at initial diagnosis. We will continue patient recruitment and start the analysis of sequential LB after tumor treatment and during follow-up."
Liquid biopsy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Oncomine™ Pan-Cancer Cell-Free Assay • Oncomine Solid Tumor DNA Kit
Share
